Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Symphogen to present positive preclinical data on Sym003 program for RSV infection
Results will be discussed at IBC's International Conference on Antibody Engineering


Copenhagen, Denmark - December 4, 2007. Symphogen A/S today announced that John Haurum, Chief Scientific Officer, will present positive preclinical data on the Company's Sym003 program against respiratory syncytial virus (RSV) at IBC's 18th Annual International Conference on Antibody Engineering in San Diego. The presentation will take place on December 5, 2007. Sym003 is a recombinant human polyclonal antibody composition that is being developed to combat RSV infection.

Preclinical data reveals that Sym003 exhibits superior potency and efficacy in a validated animal model of RSV infection. The data demonstrates enhanced antibody potency and antigen neutralization by using recombinant polyclonal antibodies, when compared to monoclonal antibodies currently marketed and in development.

'This data presentation reveals that Symphogen has a unique RSV product in preclinical development that displays superior and dose-dependent reduction of RSV replication in vivo,' said Kirsten Drejer, Ph.D., CEO of Symphogen. 'These results provide additional support for the strength of our antibody discovery technology SymplexTM and the development of recombinant polyclonal antibodies. This approach builds upon the strengths of traditional monoclonal antibodies, while also addressing nature's diverse immune response to infection. We believe that the unique product profile and the great therapeutic potential of Sym003, as evidenced by these encouraging data, will advance and accelerate our efforts to progress this candidate to the clinic.'

About Sym003

Sym003 is a recombinant polyclonal antibody product that contains antibodies binding to non-overlapping epitopes on the two major antigens on RSV, the F and G proteins. The synergistic neutralization/protective effects achieved by employing G antibodies is expected to improve the candidate's ability to block the immunomodulatory effects of RSV surface proteins, which may potentially reduce RSV-associated complications. Sym003 also possesses broad epitope and strain recognition because of its polyclonality, which may reduce the risk of clinical failure due to immune escape and resistance. The antibodies comprising Sym003 have been cloned from human starting material and therefore mimic the binding specificity and broad diversity of the natural immune system's response to combat an RSV attack.

About Symphogen

Symphogen A/S is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system. Symphogen is building a proprietary product pipeline within several disease areas, including infectious diseases and cancer. Symphogen has established collaborations with international pharmaceutical companies.

Symphogen is a private biopharmaceutical company with over 75 employees, based in Copenhagen, Denmark.

Refer to www.symphogen.com for further information on Symphogen.

Kirsten Drejer, CEO of Symphogen: +45 45 26 50 59 or +45 22 10 9959 (cell); kd@symphogen.com

John Haurum, CSO of Symphogen: +45 22 10 99 58 (cell) jh@symphogen.com

Media contact:

Douglas MacDougall, MacDougall Biomedical Communications +1 781-235-3060; doug@macbiocom.com


Publisher Contact Information:

Symphogen A/S
+45 45 26 50 59
kd@symphogen.com

Company profile of Symphogen A/S
Past press releases of Symphogen A/S.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.